Regression of Cirrhosis After HBsAg Seroconversion in a Cirrhotic 38 Year-Old Bangladeshi Man Treated with Tenofovir Disoproxil Fumarate
肝硬化38岁的孟加拉人替诺
治疗后表面抗原血清学转换,肝硬化消退
Reported by Jules Levin
Asian Pacific Association for the Study of the Liver (APASL), June 2013, Singapore
A Moore1, S Moon2, R Manch1
1Saint Joseph's Hospital and Medical Center, Phoenix, AZ, USA; 2Gilead Sciences, Foster City, CA, USA
CONCLUSIONS
• Dramatic regression of cirrhosis, and seroconversion of both HBeAg and HBsAg were achieved in this Bangladeshi patient with well-compensated cirrhosis while on tenofovir DF therapy.
• Mild steatosis is one possible explanation for persistently elevated ALT despite long-term suppression of HBV DNA and HBsAg seroconversion.
• Further data are needed to guide the decision on when to stop therapy in cirrhotic patients who seroconvert to HBsAb.
戏剧性的回归肝硬化,HBeAg和乙肝表面抗原的血清学转换,实现在孟加拉病人代偿期肝硬化,而替诺福韦治疗。